Postoperative pulmonary complications after preoperative chemoradiation for esophageal carcinoma: Correlation with pulmonary dose-volume histogram parameters

International Journal of Radiation Oncology Biology Physics

Volumn 57, Issue 5, 2003, Pages 1317-1322

  Lee, Hoon K ^a   Vaporciyan, Ara A ^a   Cox, James D ^a,b   Tucker, Susan L ^a   Putnam Jr , Joe B ^a   Ajani, Jaffer A ^a   Liao, Zhongxing ^a   Swisher, Stephen G ^a   Roth, Jack A ^a   Smythe, W Roy ^a   Walsh, Garrett L ^a   Mohan, Radhe ^a   Liu, Hui H ^a   Mooring, Deidre ^a   Komaki, Ritsuko ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Dose volume histogram; Esophageal cancer; Postoperative morbidity; Preoperative chemoradiation; Pulmonary complications

Indexed keywords

BIOMEDICAL ENGINEERING; CHEMOTHERAPY; DOSIMETRY; ONCOLOGY; PULMONARY DISEASES;

ACUTE RESPIRATORY DISTRESS SYNDROMES (ARDS);

RADIOTHERAPY;

ANTINEOPLASTIC AGENT; CAPECITABINE; CISPLATIN; DOCETAXEL; FLUOROURACIL; IRINOTECAN; PACLITAXEL;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; ESOPHAGUS CARCINOMA; FEMALE; HISTOGRAM; HOSPITAL ADMISSION; HUMAN; LENGTH OF STAY; LUNG COMPLIANCE; LUNG COMPLICATION; LUNG VOLUME; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PNEUMONIA; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION;

EID: 0345257825     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(03)01373-7     Document Type: Article

References (36)

1. Jemal A., Murray T., Samuels A., et al. Cancer statistics, 2003. CA Cancer J Clin. 53:2003;5-26.
2. Bosset J.F., Gignoux M., Triboulet J.P., et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 337:1997;161-167.
3. Minsky B.D., Pajak T.F., Ginsberg R.J., et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer High-dose versus standard-dose radiation therapy . J Clin Oncol. 20:2002;1167-1174.
4. Cooper J.S., Guo M.D., Herskovic A., et al. Chemoradiotherapy of locally advanced esophageal cancer Long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group . JAMA. 281:1999;1623-1627.
5. Urba S.G., Orringer M.B., Turrisi A., et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 19:2001;305-313.
6. Herskovic A., Martz K., al-Sarraf M., et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 326:1992;1593-1598.
7. Walsh T.N., Noonan N., Hollywood D., et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 335:1996;462-467.
8. Coia L.R., Minsky B.D., John M.J., et al. The evaluation and treatment of patients receiving radiation therapy for carcinoma of the esophagus Results of the 1992-1994 Patterns of Care Study . Cancer. 85:1999;2499-2505.
9. AJCC Cancer Staging Handbook. 6th ed. Chicago: AJCC; 2002.
10. CDC definitions for nosocomial infections, 1988. Am Rev Respir Dis 1989;139:1058-1059.
11. Bernard G.R., Artigas A., Brigham K.L., et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 149:1994;818-824.
12. Adelstein D.J., Rice T.W., Becker M., et al. Use of concurrent chemotherapy, accelerated fractionation radiation, and surgery for patients with esophageal carcinoma. Cancer. 80:1997;1011-1020.
13. Graham M.V., Purdy J.A., Emami B., et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 45:1999;323-329.
14. Sauaia A., Moore F.A., Moore E.E., et al. Early risk factors for postinjury multiple organ failure. World J Surg. 20:1996;392-400.
15. Moore F.A., Moore E.E. Evolving concepts in the pathogenesis of postinjury multiple organ failure. Surg Clin North Am. 75:1995;257-277.
16. Deitch E.A. Multiple organ failure. Pathophysiology and potential future therapy. Ann Surg. 216:1992;117-134.
17. Hassoun H.T., Kone B.C., Mercer D.W., et al. Post-injury multiple organ failure The role of the gut . Shock. 15:2001;1-10.
18. Gergel T.J., Leichman L., Nava H.R., et al. Effect of concurrent radiation therapy and chemotherapy on pulmonary function in patients with esophageal cancer Dose-volume histogram analysis . Cancer J. 8:2002;451-460.
19. Gopal R., Tucker S.L., Komaki R., et al. The relationship between local dose and loss of function for irradiated lung. Int J Radiat Oncol Biol Phys. 56:2003;106-113.
20. Lin E., Calvano S.E., Lowry S.F. Inflammatory cytokines and cell response in surgery. Surgery. 127:2000;117-126.
21. Schlag G., Redl H. Mediators of injury and inflammation. World J Surg. 20:1996;406-410.
22. Anscher M.S., Kong F.M., Andrews K., et al. Plasma transforming growth factor beta1 as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys. 41:1998;1029-1035.
23. Robnett T.J., Machtay M., Vines E.F., et al. Factors predicting severe radiation pneumonitis in patients receiving definitive chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys. 48:2000;89-94.
24. Kutcher G.J., Burman C., Brewster L., et al. Histogram reduction method for calculating complication probabilities for three-dimensional treatment planning evaluations. Int J Radiat Oncol Biol Phys. 21:1991;137-146.
25. Kutcher G.J., Burman C. Calculation of complication probability factors for non-uniform normal tissue irradiation the effective volume method . Int J Radiat Oncol Biol Phys. 16:1989;1623-1630.
26. Lyman J.T., Wolbarst A.B. Optimization of radiation therapy, IV A dose-volume histogram reduction algorithm . Int J Radiat Oncol Biol Phys. 17:1989;433-436.
27. Lyman J.T. Complication probability as assessed from dose-volume histograms. Radiat Res Suppl. 8:1985;S13-S19.
28. Niemierko A., Goitein M. Calculation of normal tissue complication probability and dose-volume histogram reduction schemes for tissues with a critical element architecture. Radiother Oncol. 20:1991;166-176.
29. Marks L.B., Munley M.T., Bentel G.C., et al. Physical and biological predictors of changes in whole-lung function following thoracic irradiation. Int J Radiat Oncol Biol Phys. 39:1997;563-570.
30. Hernando M.L., Marks L.B., Bentel G.C., et al. Radiation-induced pulmonary toxicity A dose-volume histogram analysis in 201 patients with lung cancer . Int J Radiat Oncol Biol Phys. 51:2001;650-659.
31. Vaporciyan A.A., Merriman K.W., Ece F., et al. Incidence of major pulmonary morbidity after pneumonectomy Association with timing of smoking cessation . Ann Thorac Surg. 73:2002;420-425. discussion 425-426.
32. Hulscher J.B., van Sandick J.W., de Boer A.G., et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 347:2002;1662-1669.
33. Milas L., Milas M.M., Mason K.A. Combination of taxanes with radiation Preclinical studies . Semin Radiat Oncol. 9:1999;12-26.
34. Liebmann J., Cook J.A., Fisher J., et al. In vitro studies of Taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst. 86:1994;441-446.
35. Taghian A.G., Assaad S.I., Niemierko A., et al. Risk of pneumonitis in breast cancer patients treated with radiation therapy and combination chemotherapy with paclitaxel. J Natl Cancer Inst. 93:2001;1806-1811.
36. Hanna Y.M., Baglan K.L., Stromberg J.S., et al. Acute and subacute toxicity associated with concurrent adjuvant radiation therapy and paclitaxel in primary breast cancer therapy. Breast J. 8:2002;149-153.